The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
Abstract
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful use of pixantrone as a bridge to transplant is highlighted, together with the absence of serious side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 4.2016
Ettinger, D. S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., D'Amico, T. A., Dilling, T. J., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0031 · Cited by 736
Martelli, M., Ferreri, A. J. M., Agostinelli, C., Di Rocco, A., Pfreundschuh, M., & Pileri, S. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.009 · Cited by 456
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
Moser, E. C. (2006) · Blood · doi:10.1182/blood-2005-08-3392 · Cited by 174
Gnaoui, T. E., Dupuis, J., Belhadj, K., Jaïs, J., Rahmouni, A., Copie‐Bergman, C., Gaillard, I., Diviné, M., Tabah-Fisch, I. M., Reyes, F., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm133 · Cited by 156
Chao, M. P. (2013) · Cancer Management and Research · doi:10.2147/cmar.s34273 · Cited by 99
Mondello, P., Steiner, N., Willenbacher, W., Ferrero, S., Ghione, P., Marabese, A., Pitini, V. V., Cuzzocrea, S., & Mian, M. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0103 · Cited by 39
Péan, E., Flores, B., Hudson, I., Sjöberg, J., Dunder, K., Salmonson, T., Gisselbrecht, C., Laane, E., & Pignatti, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0020 · Cited by 36
Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines
Menna, P., Salvatorelli, E., & Minotti, G. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.6b00190 · Cited by 21
Belada, D., Georgiev, P., Dakhil, S. R., Inhorn, L. F., Andorsky, D. J., Beck, J. T., Quick, D. P., Pettengell, R., Daly, R., Dean, J. P., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0137 · Cited by 17
Muszbek, N., Kadambi, A., Lanitis, T., Hatswell, A. J., Patel, D. V., Wang, L., Singer, J. W., & Pettengell, R. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.004 · Cited by 11
Zinzani, P. L., Corradini, P., Martelli, M., Minotti, G., Oliva, S., Spina, M., Barosi, G., & Tura, S. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12768 · Cited by 10
Cited by
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Metadata
- Authors
- Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M.
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 62
- Issue
- 3
- Pages
- 187-191
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2598700764
- Cited by
- 2,327
- References
- 14
- FWCI
- 111.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.